Ipilimumab: Its potential in non-small cell lung cancer

Therapeutic Advances in Medical Oncology

Volumn 4, Issue 2, 2012, Pages 43-50

  Tomasini, Pascale ^a   Khobta, Nataliya ^b   Greillier, Laurent ^b   Barlesi, Fabrice ^c  

^a University of the Mediterranean Aix Marseille II   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c HÔPITAL NORD   (France)

Author keywords

biomarkers; immunotherapy; ipilimumab; lung cancer; targeted therapy

Indexed keywords

BELAGENPUMATUCEL L; BUDESONIDE; CARBOPLATIN; CD28 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EMEPEPIMUT S; GLYCOPROTEIN GP 100; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; IPILIMUMAB; MELANOMA ANTIGEN 3; PACLITAXEL; PLACEBO; TALACTOFERRIN;

ADAPTIVE IMMUNITY; ADJUVANT CHEMOTHERAPY; ADRENAL INSUFFICIENCY; ADVANCED CANCER; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CD25+ T LYMPHOCYTE; CELL EXPANSION; CORRELATION ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DNA SEQUENCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ENTEROCOLITIS; GENETIC VARIABILITY; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; KIDNEY METASTASIS; LUNG NON SMALL CELL CANCER; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TOXIC EPIDERMAL NECROLYSIS; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR REGRESSION; UVEITIS;

EID: 84864438734     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834011431718     Document Type: Article

References (29)

1. Arriagada R. Dunant A. Pignon J.P. Bergman B. Chabowski M. Grunenwald D. et al. (2010) Long-term results of the International Adjuvant Lung Cancer Trial evaluating cisplatine-based chemotherapy in resected lung cancer. J Clin Oncol 28: 35–42.
2. Bass K.K. Mastrangelo M.J. (1998) Immunopotentiation with low-dose cyclophosphamide in the active specific immumnotherapy of cancer. Cancer Immunol Immunother 47: 1–12.
3. Beck K.E. Blansfield J.A. Tran K.Q. Feldman A.L. Hughes M.S. Royal R.E. et al. (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24: 2283–2289.
4. Bedognetti D. Balwit J.M. Wang E. Disis M.L. Britten C.M. Delogu L.G. et al. (2011) SITC / iSBTc cancer immunotherapy biomarkers resource document: online resources and useful tools – a compass in the land of biomarker discovery. J Transl Med 9: 155.
5. Breunis W.B. Tarazona-Santos E. Chen R. Kiley M. Rosenberg S.A. Chanock S.J. (2008) Influence of cytotoxic T lymphocyte- associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother 31: 586–590.
6. Brunet J.F. Denizot F. Luciani M.F. Roux-Dosseto M. Suzan M. Mattei M.G. Golstein P. (1987) A new member of the immunoglobulin superfamily – CTLA-4. Nature 328: 267–270.
7. Chmiel K.D. Suan D. Liddle C. Nankivell B. Ibrahim R. Bautista C. et al. (2011) Resolution of severe ipilimumab-induced hepatitis after antithymocyteglobulin therapy. J Clin Oncol 29: e237–e240.
8. Dillard T. Yedinak C.G. Alumkal J. Fleseriu M. (2010) Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 13: 29–38.
9. Ding L. Getz G. Wheeler D.A. Mardis E.R. McLellan M.D. Cibulskis K. et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069–1075.
10. Fong L. Kwek S.S. O'Brien S. Kavanagh B. McNeel D.G. Weinberg V. et al. (2009) Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA 4 blockade and GM-CSF. Cancer Res 69: 609–615.
11. Gabriel E.M. Lattime E.C. (2007) Anti-CTL associated antigen 4: are regulatory T cells a target? Clin Cancer Res 13: 785–788.
12. Haanen J.B. Hodi F.S. O'Day S.J. McDermott D.F. Robert C. Schadendorf D. et al. (2010) Ipilimumab improves survival in patients with previously treated advanced melanoma: long-term survival results from a phase III trial. Ann Oncol 21(Suppl. 8): 402, abstract no. 1327P.
13. Hiraoka K. Miyamoto M. Cho Y. Suzuoki M. Oshikiri T. Nakakubo Y. et al. (2006) Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 94: 275–280.
14. Hodi F.S. O'Day S.J. McDermott D.F. Weber R.W. Sosman J.A. Haanen J.B. et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711–723.
15. Lawrence D.P. Hamid O. McDermott D.F. Puzanov I. Sznol M. Clark J. et al. (2010) Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. J Clin Oncol 28(Suppl.): abstract no. 8523.
16. Leach D.R. Krummel M.F. Allison J.P. (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734–1736.
17. Lebbé C. McDermott D.F. Robert C. Lorigan P. Ottensmeier C.H. Wolchok J. et al. (2010) Ipilimumab improves survival in previously treated advanced melanoma patients with poor prognosis factors: subgroup analyses from a phase III trial. Ann Oncol 21(Suppl. 8): 401, abstract no. 13240.
18. Lynch T.J. Bondarenko I.N. Luft A. Serwatowski P. Barlesi F. Chacko R.T. et al. (2010) Phase II trial of ipilimumab and paclitaxel / carboplatin in first-line stage IIIb / IV non-small cell lung cancer. J Clin Oncol 28(Suppl.): 208, abstract no. 7531.
19. Lynch T.J. Bondarenko I.N. Luft A. Serwatowski P. Barlesi F. Chacko R.T. et al. (2011) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in non-small cell lung cancer: analysis by baseline histology in a phase 2 trial. WCLC abstract no. 701.
20. Min L. Vaidya A. Becker C. (2011) Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 164 (2): 303–307.
21. Morgensztern D. Goodgame B. Govindan R. (2010) Vaccines and immunotherapy for non-small cell lung cancer. J Thorac Oncol 5(12 Suppl. 6): S463–S465.
22. O'Mahony D. Morris J.C. Quinn C. Gao W. Wilson W.H. Gause B. et al. (2007) A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancies. Clin Cancer Res 13: 958–964.
23. Parikh P.M. Vaid A. Advani S.H. Digumarti R. Madhavan J. Nag S. et al. (2011) Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol 29: 4129–4136.
24. Vansteenkiste J. Zielinski M. Linder A. Dahabre J. Esteban E. Malinowski W. et al. (2007) Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB / II non-small cell lung cancer (NSCLC). J Clin Oncol 25(Suppl.): 398s, abstract no. 7554.
25. Weber J. Thompson J.A. Hamid O. Minor D. Amin A. Ron I. et al. (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15: 5591–5598.
26. Weber J.S. Hamid O. Wolchok J. Amin A. Masson E. Goldberg S. et al. (2010) Assessment of pharmacokinetic interaction between ipilimumab and chemotherapy in a randomized study. Ann Oncol 21(Suppl. 8): 403, abstract no. 1329P.
27. Wolchok J.D. Hoos A. O'Day S. Weber J.S. Hamid O. Lebbe C. et al. (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15: 7412–7420.
28. Yang A. Kendle R.F. Ginsberg B.A. Roman R. Heine A.I. Pogoriler E. et al. (2010) CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: correlation with clinical outcomes. J Clin Oncol 28(Suppl.): abstract no. 2555.
29. Yang J.C. Hughes M. Kammula U. Royal R. Sherry R.M. Topalian S.L. et al. (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30: 825–830.